Cabometyx cabozantinib: Additional Phase III data

Additional data from the open-label, international Phase III METEOR trial in 658 metastatic RCC patients who progressed after >=1 VEGF receptor tyrosine kinase inhibitor (TKI)

Read the full 257 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE